1-7 of 7
Ines Kaupe
Close
Sort by
Journal Articles

Bcr-Abl Directly Activates Stat5 Independent of Jak2

Oliver D. Hantschel, MSc, PhD, Eva Eckelhart, MSc, Ines Kaupe, MSc, Florian Grebien, MSc, PhD, Kay-Uwe Wagner, PhD, Veronika Sexl, MD, Giulio Superti-Furga, PhD
Journal: Blood
Blood (2010) 116 (21): 511.
https://doi.org/10.1182/blood.V116.21.511.511
Published: 2010
Journal Articles

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Daniel W. Sherbenou, Oliver Hantschel, Ines Kaupe, Stephanie Willis, Thomas Bumm, Lalita P. Turaga, Thoralf Lange, Kim-Hien Dao, Richard D. Press, Brian J. Druker, Giulio Superti-Furga, Michael W. Deininger
Journal: Blood
Blood (2010) 116 (17): 3278–3285.
https://doi.org/10.1182/blood-2008-10-183665
Published: 2010
Includes: Supplemental data
Journal Articles

The Bcr-Abl SH2-Kinase Domain Interface Is Critical for Leukemogenesis and An Additional Therapeutic Target in CML.

Oliver D. Hantschel, PhD, Florian Grebien, Ines Kaupe, Boris Kovacic, John Wojcik, Gerald D Gish, Shohei Koide, Hartmut Beug, Tony Pawson, Giulio Superti-Furga
Journal: Blood
Blood (2009) 114 (22): 37.
https://doi.org/10.1182/blood.V114.22.37.37
Published: 2009
Journal Articles

Structural Positioning of the SH2 Domain Is Critical for Bcr-Abl Kinase Activity, Signal Transduction and Oncogenic Transformation

Oliver D. Hantschel, PhD, Florian Grebien, Ines Kaupe, Giulio Superti-Furga
Journal: Blood
Blood (2008) 112 (11): 569.
https://doi.org/10.1182/blood.V112.11.569.569
Published: 2008
Journal Articles

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

Uwe Rix, Oliver Hantschel, Gerhard Dürnberger, Lily L. Remsing Rix, Melanie Planyavsky, Nora V. Fernbach, Ines Kaupe, Keiryn L. Bennett, Peter Valent, Jacques Colinge, Thomas Köcher, Giulio Superti-Furga
Journal: Blood
Blood (2007) 110 (12): 4055–4063.
https://doi.org/10.1182/blood-2007-07-102061
Published: 2007
Includes: Supplemental data
Journal Articles

Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia.

Daniel W. Sherbenou, BA, Oliver J. Hantschel, PhD, Lalita Turaga, BS, Ines Kaupe Mag, Stephanie Willis, BS, Thomas Bumm, MD, Richard D. Press, MD, PhD, Giulio Superti-Furga, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2936.
https://doi.org/10.1182/blood.V110.11.2936.2936
Published: 2007
Journal Articles

Systematic Profiling and Novel Targets of the Bcr-Abl Kinase Inhibitors Imatinib, Nilotinib and Dasatinib.

Oliver Hantschel, PhD, Uwe Rix, PhD, Tilmann Buerckstuemmer, PhD, Uwe Schmidt, PhD, Michael Kneidinger, MD, Keiryn L. Bennett, PhD, Ines Kaupe, BSc, Wilfried Ellmeier, PhD, Peter Valent, MD, Giulio Superti-Furga, PhD
Journal: Blood
Blood (2007) 110 (11): 4542.
https://doi.org/10.1182/blood.V110.11.4542.4542
Published: 2007